Introduction
In the inflammatory response, leukocyte recruitment to the endothelium is mediated by the interaction of adhesion molecule receptors expressed on the surface ofendothelial cells with counterreceptors expressed on immune cells. Endothelial cells cule-1 (ICAM-1 ), or E-selectin, in response to various inflammatory stimuli ( 1, 2) . An important example ofthis process is the localized endothelial expression of VCAM-1 and selective recruitment of mononuclear leukocytes to the vascular lesions observed in early atherosclerosis (3) . VCAM-1 is a member of the immunoglobulin gene superfamily that mediates leukocyte binding to the endothelial cell through its interaction with its integrin counterreceptor, very late activation antigen-4 (VLA-4) (4). Because ofthe selective expression ofVLA-4 on monocytes and lymphocytes, but not neutrophils, VCAM-1 plays an important role in mediating mononuclear leukocyte-selective adhesion (4) (5) (6) (7) (8) (9) .
The nature of the inflammatory signals and associated molecular mechanisms that activate VCAM-1 gene expression in endothelial cells in the early atherogenic lesion are unknown. Whether similar or distinct mechanisms regulate ICAM-I gene expression in the atherosclerotic setting is also unknown (3, 10, 11) . Factors commonly found in inflammatory atherogenic lesions, such as the cytokines TNFa and IL-1A, induce the concurrent expression of VCAM-1, ICAM-1, and E-selectin in cultured endothelial cells (see reference 2 for review). This same pattern of expression is observed in culture with other agents such as bacterial endotoxin LPS and the synthetic double-stranded RNA, polyinosinic:polycitidylic acid, poly(I:C) (PIC) (12) (13) (14) . Clearly, these factors alone cannot selectively activate VCAM-1 gene expression and this raises the issue of whether these factors activate VCAM-1, ICAM-1, and E-selectin expression through a common, or gene-specific, molecular regulatory pathway. Evidence for a VCAM-1-specific regulatory mechanism is suggested by the observation that IL-4 enhances TNFa activation of endothelial VCAM-l expression ( 15 ) but represses TNFa activation of ICAM-I and E-selectin expression ( 16) . This raises the possibility that in addition to IL-4, other types of regulatory signals may interact with elements of a VCAM-1-specific regulatory mechanism to either activate or repress VCAM-1 expression independent ofICAM-1 or E-selectin.
Oxidative stress may play an important role in regulating VCAM-1 gene expression. In the early atherogenic lesion, oxi- dative stress is manifested by the elevated production of reactive oxygen species by endothelial and smooth muscle cells that result in the oxidative modification of low density lipoprotein ( 17, 18) . This is likely due in part to both paracrine and autocrine mechanisms by which the cytokines IL-1l3 and TNFa, derived from both inflammatory and endothelial cells, induce the cellular synthesis ofreactive oxygen species ( 19, 20) . It is in this oxidative milieu that endothelial VCAM-I expression and consequent monocyte accumulation is observed in the early atherogenic lesion (3, 21 ) . These observations suggest that the activation of VCAM-1 gene expression might be distinguished by its sensitivity to modulation by oxidation-mediated signals.
Recent studies of the human VCAM-1 promoter suggest that TNFa activation of VCAM-1 transcription in endothelial cells is dependent, at least in part, on the activation of NF-KBlike transcriptional regulatory proteins (22, 23) . NF-KB is a ubiquitously expressed multisubunit transcription factor whose activation in several cell types by a large and diverse group of agents such as TNFa, IL-I,3, LPS, PIC, as well as the oxidant H202 can be specifically inhibited by antioxidants such as N-acetylcysteine (NAC) and pyrrolidine dithiocarbamate (PDTC) (24) (25) (26) . This has led to the hypothesis that oxygen radicals play an important role in the activation of NF-KB through an as yet undefined reduction-oxidation (redox) mechanism (26) . By extrapolation, oxidative stress in the atherosclerotic lesion may play a role in regulating VCAM-1 gene expression through an NF-KB-like redox sensitive transcriptional regulatory protein.
We have tested the hypothesis that cytokines selectively induced VCAM-1 gene regulation through an antioxidant sensitive pathway in human umbilical vein endothelial (HUVE) cells. We have identified a regulatory pathway controlling VCAM-1 expression that is sensitive to antioxidants and distinct from ICAM-1 and E-selectin expression. In the process, we have shown a possible molecular linkage between redox sensitive regulatory mechanisms in the endothelial cell and VCAM-1 gene transcription and expression that expands on the notion of oxidative stress as an important regulatory signal in the expression ofVCAM-I in the pathogenesis ofatherosclerosis.
Methods
Cell culture. HUVE cells were isolated from human umbilical veins that were cannulated, perfused with Hanks' solution to remove blood, and then incubated with 1% collagenase for 15 min at 37°C. After removal of collagenase, cells were cultured in Ml 99 medium supplemented with 20% FBS (HyClone Laboratories, Logan, UT), 16 Northern blot analysis. Total cellular RNA was isolated by a single extraction using an acid guanidium thiocyanate-phenol-chloroform (27) . Total cellular RNA (20 Mg) was size-fractionated using 1% agarose formaldehyde gels in the presence of 1 ug/ml ethidium bromide. 32P-labeled DNA probes were prepared using the random primer oligonucleotide method (28) . The VCAM-I probe was a Hind III-Xho I fragment of the human cDNA consisting of nucleotides 132-1814 (29) . The ICAM-l probe was an Eco RI fragment of human cDNA (30) . The 40 ,tg of protein of each cell extract was assayed for chloramphenicol acetyl transferase (CAT) activity and reaction were done in 4 h according to standard protocols (32) . Each assay was performed in duplicate from at least two separate experiments. The reporter plasmid p288VCAM-CAT (22) was a generous gift of Dr. Douglas Dean (Washington University). Nuclear extract preparation and gel shift analysis. Confluent HUVE cells were pretreated for 1 h or untreated with 100 MM PDTC, then exposed to either TNFa (100 U/ml) or LPS (100 ng/ml) for I h. Nuclear proteins were purified by a modification of (34) . Briefly, after washing with phosphate-buffered saline, cells were centrifuged and the cell pellet suspended in 500,l buffer A (10mM Hepes, pH 7.9, 1.5mM MgCI2, 10 mM KCl, and 1.0 mM DTT). After recentrifugation, the cells were resuspended in 80 Ml buffer A containing 0.1% Triton-X-100 by gentle pipetting. After incubating for 10 min at 4VC, the homoge- mM Tris, 60 mM KCl, 1 mM EDTA, 12% glycerol, 1 mM DTT, and 1 mM PMSF) with or without 20-100-fold molar excess ofcold competitor. Samples were subjected to electrophoresis on native 4% 1 X Trisglycine-polyacrylamide gels.
Results
The antioxidant PDTC inhibits cytokine and noncytokine induction of VCAM-J, but not ICAM-J or E-selectin, mRNA accumulation in HUVE cells. To explore whether the IL-I/ activated VCAM-1 gene expression through an oxidation-dependent mechanism, HUVE cells were exposed to the inducing cytokine, IL-I 3 (10 U/ml) in the presence or absence of the antioxidant PDTC (50 ,uM) for up to 24 h. PDTC is a dithiocarbamate that can function as an antioxidant through direct delivery of thiol groups to the cell (26) . As shown in To explore whether PDTC-sensitive activation ofVCAM-I gene expression was specific for IL-13, other structurally and functionally distinct inducers of VCAM-l gene expression were tested. PDTC selectively inhibited TNFa, LPS, and PICmediated induction of VCAM-l mRNA accumulation in HUVE cells after 4 h (Fig. 2 A) . Interestingly, PDTC partially inhibited E-selectin activation by TNFa but not by LPS or PIC (Fig. 2 B) . PDTC slightly augmented ICAM-1 induction in response to LPS but had no effect on TNFa or PIC mediated activation (Fig. 2 C) . These results suggest that PDTC-sensitive activation is a fundamental feature of VCAM-1 gene expression regardless of the inducing agent. In contrast, whether activation of the E-selectin genes is PDTC-sensitive or PDTCinsensitive signals appears to be dependent on the specific inducer. ICAM-1 gene expression was not affected by any activators so far tested. Fig. 3 , the structurally unrelated NAC effectively inhibited IL-1(3 activation of VCAM-1 mRNA accumulation although at considerably higher concentrations than PDTC. This concentration was established by dose-response studies (data not shown) and correlated well with the ability of NAC to inhibit the expression of other redox-sensitive genes and transcriptional regulatory proteins (24) . These results suggest that structurally distinct antioxidants may inhibit a common, oxidationsensitive regulatory step that activates VCAM-1 gene expression.
PDTC blocks the induction offunctional VCAM-J protein expression. To establish formally that PDTC blocked activation of functional VCAM-1, both VCAM-1 protein accumulation and VCAM-1-mediated cell adhesion were measured. VCAM-l (4B9 [6] ) and ICAM-l (84H10 [35 ] ) specific mAbs were used in an ELISA assay to quantitate the induction of cell surface VCAM-1 and ICAM-1 in cultured HUVE cells. As shown in Fig. 4, VCAM-1 'ar 0.050~_ Fig. 6 , PDTC had no effect on pSV2CAT activity (duplicate experiments, lanes [11] [12] [13] [14] suggesting that the mechanism by which PDTC blocks VCAM-1 promoter activation is not due to a (37) and ICAM-1 (38) .
Although an effect on a redox mechanism is inferred, this study does not identify the specific redox biochemistry mediating PDTC's regulatory effect. However, our studies indirectly suggest that PDTC functions through mechanisms related to its thiol antioxidant properties. In support of this, the structurally unrelated, thiol antioxidant NAC also effectively inhibited the activation of VCAM-1. Similar results were obtained with another dithiocarbamate, diethyldithiocarbamate (data not shown). Whether these are due to redox reactions involving direct modification by an oxygen radical or through glutathione-dependent oxidation reactions is not yet known. In support of glutathione-dependent redox reactions, both dithiocarbamates and NAC are effective thiol delivery agents that increase intracellular levels of glutathione (39) . In addition, we have observed that an agent that depletes glutathione level in the cell, L-buthionine-sulfoximine, augmented VCAM-1 expression in response to cytokine activation (Marui and Medford, manuscript in preparation). In support ofdirect modification by an oxygen radical, TNFa and IL-1 induce the synthesis of oxygen radicals in both lymphoid and nonlymphoid cells ( 19, 20) . NAC and dithiocarbamates may also react directly with oxygen radicals induced by various activators in HUVE cells while dithiocarbamates may inhibit oxygen radical formation through chelation of intracellular metal ions and blockade of the Haber-Weiss-Fenton reaction (40) . An NF-KB is a ubiquitously expressed multisubunit transcription factor that is activated by diverse signals (see reference 41 for review) possibly through phosphorylation of the IKB subunit and its dissociation from the inactive cytoplasmic complex followed by translocation of the active dimer of p50 and p65 to the nucleus (42) . Antioxidants such as NAC and other cysteine derivatives inhibit NF-KB-driven transcription of the HIV-1 (25, 43, 44) and HIV-1 viral replication (43) . In several immortalized cell lines, NF-KB is activated by diverse stimuli such as TNFa, IL-1 F, LPS, and PIC, and inhibited by the antioxidants PDTC and NAC (24, 25 (37, 45 ). Yet, we found that PDTC did not inhibit the induction of E-selectin mRNA levels. The inhibition of NF-KB-like activation but not E-selectin gene expression by PDTC argues against NF-KB-like transcriptional factors as essential components in E-selectin gene activation. Similarly, these same inducible factors do not appear to be essential in the activation of ICAM-1 expression despite the presence of NF-KB consensus DNA binding sites on the ICAM-1 promoter (46, 47) .
These apparently conflicting conclusions on the role of NF-KB in endothelial cell gene expression illustrate both differences in experimental approach as well as the complexity of the NF-KB transcriptional complex. The notion of a "consensus" NF-KB DNA binding site has been called into question as different "consensus" sites appear to elicit very different binding and transcriptional activation properties of NF-KB (48) . Similarly, differential competition for NF-KB binding sites by the p50/ p65 heterodimer (NF-KB) or p50 and p65 homodimers may be determined by slight differences in the DNA "consensus" sequence (49) . The interaction of NF-KB with other transcriptional factors might also influence binding and transactivation of VCAM-1 and thus the association of the NF-KB site with other DNA binding sites is likely crucial (22, 23). In the case of E-selectin, other additional transcriptional and posttranscriptional mechanisms regulate E-selectin gene expression (37) . The relative contributions of NF-KB and these other factors in regulating E-selectin gene expression are not known. Furthermore, in contrast to E-selectin, which has only one NF-KB site, VCAM-1 has two closely linked NF-KB binding sites. The 5' NF-KB binding site shows incomplete consensus sequence by one base (50), yet both sites are necessary for activation of VCAM-1 gene (22, 23). As each of these sites may bind differ-ent protein complexes, the interaction between both NF-KB binding sites may contribute to the transactivation of the VCAM-I gene (22, 23).
Tissue-specific, transformation-specific and possibly cytokine-specific factors may both play roles in modulating adhesion molecule gene expression. Indeed, we did observe a modest decrease in the peak E-selectin mRNA accumulation in PDTC-treated HUVE cells exposed to TNFa but not to IL-13, LPS or PIC after 4 h. This raises the possibility that TNFa and IL-13 may activate E-selectin gene expression through distinct molecular mechanisms distinguishable by their sensitivity to inhibition by PDTC. In human dermal microvascular endothelial cells, TNFa but not IL-1 induces VCAM-l while both TNFa and IL-1 each induce ICAM-1 expression ( 15) . These studies support the notion that TNFa and IL-1 may function through distinct molecular mechanisms in endothelial cells.
Tissue-specific and/or transformation-specific transcriptional regulatory factors may also play a role in regulating ICAM-1 gene expression. Deletion analysis of the 5' flanking region of the ICAM-1 promoter demonstrates that an NF-KB binding site serves as a transcriptional activator in adenocarcinoma and fibrosarcoma cell lines (46) but is apparently not necessary for cytokine activation in primary human vascular endothelial cells (W. Caughman, personal communication).
Our study does not address the important issue of whether the ICAM-1 or E-selectin NF-KB-like elements regulate cytokine activation of either promoter through a PDTC-sensitive or -insensitive process in primary HUVE cells. Thus, the precise molecular mechanism (s) by which E-selectin and ICAM-1 gene expression "escapes" inhibition by PDTC remains an important unresolved question. To determine whether PDTC sensitive transcriptional regulation is restricted to VCAM-1 or is a feature of other vascular endothelial genes will require a comprehensive survey of transcriptional responses. To this end, we have identified the cytokine IL-6 gene as exhibiting a similar pattern of PDTC-sensitive cytokine activation as VCAM-1 in human vascular endothelial cells (M. Offermann, personal communication). Interestingly, NF-KB activation also plays an important role in the regulation of IL-6 gene expression (51, 52). This suggests that PDTC-sensitive regulation of gene expression may define a distinct network of genes involved in inflammation and in the atherosclerotic setting.
Atherosclerosis is a chronic disease of the arterial intima characterized by the focal accumulation of leukocytes, smooth muscle cells, lipids, and extracellular matrix. Current hypotheses concerning its pathogenesis focus on the modification of LDL into oxidatively-modified LDL (ox-LDL) (53) . For example, inhibition of LDL oxidation with the antioxidant probucol (53) inhibits the progression of atherosclerotic lesions in LDL receptor-deficient rabbits (54, 55) . Our studies suggest the mechanism by which antioxidants inhibit atherosclerosis may not be solely due to their ability to inhibit oxidation of LDL. Probucol and other antioxidants may also function by blocking specific, intracellular, redox-sensitive signal transduction pathways involved in atherogenesis. Thus, a therapeutically important feature of antioxidants in atherosclerosis may be due to direct alterations in the metabolism and function of endothelial, smooth muscle, and inflammatory cells. Our studies establish a potential molecular linkage between the redox state of the vascular endothelial cell and VCAM-1 gene expression that expands on the notion of oxidation as an important intracellular regulatory signal that mediates the selective expression of VCAM-1 and consequent mononuclear leukocyte accumulation observed early in the pathogenesis of atherosclerosis.
Our studies suggest that an increase in the endothelial cell oxidative state may sensitize the vasculature to otherwise physiologic signals resulting in abnormally elevated expression of adhesion molecules such as VCAM-1 and other gene products involved in the inflammatory response. Conversely, the maintenance of a low endothelial oxidative state may desensitize the vasculature to normal or even elevated levels of these same signals. In this context, the specific target of either natural or synthetic antioxidants would be specific regulatory factor(s) that transduces metabolic signals (i.e., oxidation) into nuclear regulatory signals (i.e., expression of adhesion molecule genes). In addition to atherosclerosis, this model may have significant therapeutic implications in a variety ofother disease states involving VCAM-1 expression.
